Beta-Defensin vs Vilon
A side-by-side research comparison of Beta-Defensin and Vilon across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Beta-Defensin | Vilon |
|---|---|---|
| Full name | Human Beta-Defensin Peptides | Vilon (Lys-Glu Dipeptide Immune Bioregulator) |
| Category | Immune Support | Immune Support |
| Status | Research compound | Research compound (peptide bioregulator) |
| Mechanism | Form pores in microbial membranes causing lysis, recruit immune cells via CCR6 receptor chemotaxis, and bridge innate and adaptive immunity by activating dendritic cells. | As a very short signal peptide (Lys-Glu), it is proposed to bind DNA and modulate gene expression in immune and other tissues, influencing chromatin activity, cytokine balance, and cellular aging markers. |
| Molecular weight | 4000-5000 Da | ~275 Da |
| Half-life | ~2-4 hours | Short (peptide) |
| Bioavailability | Primarily local/mucosal activity | Oral (encapsulated) or subcutaneous |
| Typical dose | 50-200 mcg | ~1-2 capsules/day or short injectable courses |
| Frequency | Daily or as needed | Once daily |
| Route | Topical or subcutaneous | Oral capsule or subcutaneous |
Beta-Defensin reported benefits
- Broad antimicrobial activity
- Immune cell recruitment
- Wound healing support
- Biofilm disruption
Vilon reported benefits
- Immune regulation support
- Gene-expression modulation (proposed)
- Anti-aging tissue effects (proposed)
- Short course-based protocol
Related comparisons
Research and educational reference only. Not medical advice.